RxDoctor Payments Data

Cuckoo Choudhary, MD

Gastroenterology · Phila, PANPI 1871552711

Payments from drug & device makers

$6,520in general payments, 2019–2025

Across 47 payments — averaging $138.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
  • Ardelyx, Inc.$2K
  • AbbVie$191
  • Johnson & Johnson$149
  • Janssen Scientific Affairs, LLC$123
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • plus $319 from 11 others

What the payments were for

  • Consulting fees$1,50023%
  • Speaking & faculty fees$4,16664%
  • Food & beverage$85413%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,520 in reported general payments places this provider in the 70th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,217
Medicare patients
364
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab43$431,093
StelaraUstekinumab13$360,406
RinvoqUpadacitinib26$269,275
LinzessLinaclotide72$62,095
Mesalamine40$47,363
XifaxanRifaximin11$24,966
TrulancePlecanatide14$10,987
Sucralfate49$10,619
Mesalamine ErMesalamine15$10,235
DexilantDexlansoprazole17$7,382
Dexlansoprazole DrDexlansoprazole21$6,496
Pantoprazole Sodium297$6,084
Colestipol Hcl60$5,239
Esomeprazole Magnesium59$5,165
Lubiprostone26$5,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$149$360,40613 claims
AbbVieRinvoq, Linzess$191$331,36998 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$4,180$35,95325 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$59$7,38217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →